Campher-10-carbonsaeure | 138299-80-6

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: Campher-10-carbonsaeure
• 英文别名: (7,7-dimethyl-2-oxo-[1]norbornyl)-acetic acid；(7,7-Dimethyl-2-oxo-[1]norbornyl)-essigsaeure；2-(7,7-Dimethyl-2-oxo-1-bicyclo[2.2.1]heptanyl)acetic acid
• CAS: 138299-80-6
• 化学式: C₁₁H₁₆O₃
• 分子量: 196.246
• InChiKey: QBRLZOFIDCWNGK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.82
• 拓扑面积：
  54.4
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  10-Carboxy-isoborneol-lacton 在 chromium(VI) oxide 、 lithium aluminium tetrahydride 作用下， 生成 Campher-10-carbonsaeure
  参考文献：
  名称：

  Lactonization of camphene-8-carboxylic acid

  摘要：

  DOI：

  10.1021/jo00827a025

文献信息

• Pyrazolones as inhibitors of 11B-hydroxysteroid dehydrogenase
  申请人：Banner Lester Bruce

  公开号：US20070049632A1

  公开（公告）日：2007-03-01

  Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of diseases such as, for example, type II diabetes mellitus and metabolic syndrome.

  本文提供了以下式(I)的化合物： 以及其药学上可接受的盐，其中取代基如规范中所披露的那样。这些化合物及含有它们的药物组合物对于治疗诸如II型糖尿病和代谢综合征等疾病是有用的。
• Process for preparing enantiomerically pure 1,1'-spirobiindane-6,6'-diol derivatives
  申请人：Welter R. Thomas

  公开号：US20060020150A1

  公开（公告）日：2006-01-26

  The present invention relates to a method for the chemical separation of the enantiomers of 1,1′-spirobiindane-6,6′-diol derivatives comprising providing a racemic chiral 1,1′-spirobiindane-6,6′-diol derivative, reacting a nonracemic chiral component with the racemic chiral 1,1′-spirobiindane-6,6′-diol derivative to afford a mixture of diastereomeric diesters, separating the mixture of diastereomeric diesters to provide a substantially pure individual diastereomeric diester, and chemically removing the ester groups from the substantially pure individual diastereomeric diester to provide a nonracemic chiral 1,1 ′-spirobiindane-6,6′-diol derivative.

  本发明涉及一种化学分离1,1'-螺环二茚-6,6'-二醇衍生物对映体的方法，包括提供一个外消旋手性的1,1'-螺环二茚-6,6'-二醇衍生物，将一个非外消旋手性成分与外消旋手性的1,1'-螺环二茚-6,6'-二醇衍生物反应，得到一种二对映异构二酯混合物，分离该二对映异构二酯混合物以提供一种基本纯净的单个二对映异构二酯，然后从该基本纯净的单个二对映异构二酯中化学去除酯基，得到一个非外消旋手性的1,1'-螺环二茚-6,6'-二醇衍生物。
• Glass-forming liquid crystalline compositions and optical devices formed therefrom
  申请人：——

  公开号：US20010036517A1

  公开（公告）日：2001-11-01

  A glass-forming liquid crystal composition comprises a compound having a molecular weight in the range of about 1000 to 5000 grams per mole and having the formula (NEM) x —CYC—(CHI) y wherein CYC is a substituted cycloaliphatic core moiety containing about 24 to about 60 carbon atoms or a substituted aromatic core moiety containing about 6 to about 36 carbon atoms, NEM is a nematogenic pendant moiety, CHI is a chiral pendant moiety, x is 3 to 9, and y is 0 to 4. An optical device is formed from the liquid crystal composition.

  一种玻璃形成液晶组合物，包括具有分子量在约1000至5000克/摩尔范围内的化合物，其具有公式（NEM）x—CYC—（CHI）y，其中CYC是含有约24至约60个碳原子的取代环状脂肪核心基团或含有约6至约36个碳原子的取代芳香核心基团，NEM是向列型挂链基团，CHI是手性挂链基团，x为3至9，y为0至4。从液晶组合物形成光学器件。
• Hybrid onium salt
  申请人：Ishihara Masami

  公开号：US20050020710A1

  公开（公告）日：2005-01-27

  The present invention relates to a hybrid type onium salt having an iodonium salt and a sulfonium salt in the molecule, useful, for example, as a cationic type photopolymerization initiator and an acid generator for a chemically amplified resist and provides a hybrid type onium salt shown by the general formula [1]: [wherein R 1 to R 3 are each independently a halogen atom, an alkyl group, a haloalkyl group, an aryl group, an alkoxy group, an aryloxy group, an alkylthio group, an arylthio group or an amino group which maybe substituted; Q 1 is a direct-linkage, an oxygen atom, a sulfur atom or a lower alkylene chain; T 1 is an alkylene group or an arylene group, which may have a substituent selected from the group consisting of a halogen atom, an alkyl group, a haloalkyl group, an aryl group, an alkoxy group, an aryloxy group, an alkylthio group, an arylthio group and an amino group which may be substituted; and R 4 is an alkyl group, an alkenyl group, an aryl group or an aralkyl group, which may have a substituent selected from the group consisting of a halogen atom, an alkyl group, a haloalkyl group, an aryl group, an alkoxy group, an aryloxy group, an alkylthio group, an arylthio group and an amino group which may be substituted or a group shown by the general formula [2]: (wherein R 5 to R 7 are each independently a halogen atom, an alkyl group, a haloalkyl group, an aryl group, an alkoxy group, an aryloxy group, an alkylthio group, an arylthio group or an amino group which maybe substituted; Q 2 is a direct-linkage, an oxygen atom, a sulfur atom or a lower alkylene chain; T 2 an alkylene group or an arylene group, which may have a substituent selected from the group consisting of a halogen atom, an alkyl group, a haloalkyl group, an aryl group, an alkoxy group, an aryloxy group, an alkylthio group, an arylthio group and an amino group which may be substituted; A 3 is a counter anion; m is an integer of 0 to 4; and two ns are each independently an integer of 0 to 5); A 1 and A 2 are each independently a counter anion; and m and n are the same as described above], and a polymerization initiator or an acid generator, comprising said onium salt.

  本发明涉及一种杂化型离子盐，其分子中具有碘化离子盐和亚砜盐，例如，作为阳离子型光聚合引发剂和化学放大型抗蚀剂的酸发生剂有用，并提供由通式[1]所示的杂化型离子盐：[其中R1至R3分别独立地是卤素原子、烷基、卤代烷基、芳基、烷氧基、芳氧基、烷硫基、芳硫基或氨基，可被取代；Q1是直链、氧原子、硫原子或较低的烷基链；T1是烷基或芳基，可具有从卤素原子、烷基、卤代烷基、芳基、烷氧基、芳氧基、烷硫基、芳硫基和可被取代的氨基中选择的取代基；R4是烷基、烯丙基、芳基或芳基烷基，可具有从卤素原子、烷基、卤代烷基、芳基、烷氧基、芳氧基、烷硫基、芳硫基和可被取代的氨基中选择的取代基或由通式[2]所示的基：（其中R5至R7分别独立地是卤素原子、烷基、卤代烷基、芳基、烷氧基、芳氧基、烷硫基、芳硫基或氨基，可被取代；Q2是直链、氧原子、硫原子或较低的烷基链；T2是烷基或芳基，可具有从卤素原子、烷基、卤代烷基、芳基、烷氧基、芳氧基、烷硫基、芳硫基和可被取代的氨基中选择的取代基；A3是一个对离子；m是0到4的整数；两个n各自独立地是0到5的整数）；A1和A2各自独立地是一个对离子；m和n与上述描述相同]，以及包含该离子盐的聚合引发剂或酸发生剂。
• NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS AND USES THEREOF
  申请人：Florjancic S. Alan

  公开号：US20080064699A1

  公开（公告）日：2008-03-13

  The present invention relates to compounds of formula (I), or pharmaceutically acceptable salts, prodrugs, salts of prodrugs, or combinations thereof, wherein R 1 , R 2 , R 3 , R 4 , and L 2 , are defined in the specification, compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions.

  本发明涉及式（I）的化合物，或其药学上可接受的盐，前药，前药盐或其组合物，其中R1，R2，R3，R4和L2在规范中有定义，包括这些化合物的组合物，以及使用这些化合物和组合物治疗疾病和病症的方法。